TNFRSF17 and plasma cell myeloma: The most prominent example is Ciltacabtagene Autoleucel (Carvykti), a VHH-based CAR-T therapy targeting BCMA, which received FDA approval in 2022 for the treatment of relapsed or refractory multiple myeloma [18].